Silymarin reduced cisplatin-induced hyperalgesia bysuppressing oxidative stress in male rats

IF 0.3 Q4 PHYSIOLOGY

Physiology and Pharmacology Pub Date : 2021-07-01 DOI:10.32598/PPJ.25.2.60

A. Nayebi, A. Hashemian, H. Rezazadeh, M. Charkhpour, K. Fekri, Rasool Haddadi

{"title":"Silymarin reduced cisplatin-induced hyperalgesia bysuppressing oxidative stress in male rats","authors":"A. Nayebi, A. Hashemian, H. Rezazadeh, M. Charkhpour, K. Fekri, Rasool Haddadi","doi":"10.32598/PPJ.25.2.60","DOIUrl":null,"url":null,"abstract":"Introduction: Cisplatin is an antineoplastic agent which is used in treatment of various cancers. However its clinical use is associated with oxidative stress-mediated neuropathic pain. This research aimed to explore the effect of silymarin on cisplatin-induced hyperalgesia (CIH) and oxidative stress biomarkers in male rats. Methods: Fifty-six male rats were allocated into seven equal groups. Hyperalgesia was caused by intraperitoneal single dose administration of cisplatin (1mg/kg) and assessed by utilizing tail-flick method. The impact of silymarin (25, 50 and 100 mg/kg/day for 15 days) on CIH was investigated on days 1, 5, 10 and 15. Blood samples were collected to assess malondialdehyde (MDA), glutathione peroxidase (GPx), superoxide dismutase (SOD) and total antioxidant status (TAS) on day fifteen. Results: Single dose injection of cisplatin (1mg/kg) could cause a significant hyperalgesia on days 5, 10 and 15. CIH was abolished by daily administration of silymarin (50 and 100mg/kg) on days 10 and 15. Serum MDA level was decreased in cisplatin and silymarin (100 mg/kg) co-treated rats, while there was an increase in GPx, SOD as well as TAS parameters. Conclusion: The results of this study revealed that silymarin prevents from CIH possibly by improving lipid peroxidation and oxidative stress biomarkers. Other clinical studies should be performed to establish possible use of silymarin for treatment of CIH in susceptible individuals.","PeriodicalId":20151,"journal":{"name":"Physiology and Pharmacology","volume":"198 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Physiology and Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/PPJ.25.2.60","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHYSIOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction: Cisplatin is an antineoplastic agent which is used in treatment of various cancers. However its clinical use is associated with oxidative stress-mediated neuropathic pain. This research aimed to explore the effect of silymarin on cisplatin-induced hyperalgesia (CIH) and oxidative stress biomarkers in male rats. Methods: Fifty-six male rats were allocated into seven equal groups. Hyperalgesia was caused by intraperitoneal single dose administration of cisplatin (1mg/kg) and assessed by utilizing tail-flick method. The impact of silymarin (25, 50 and 100 mg/kg/day for 15 days) on CIH was investigated on days 1, 5, 10 and 15. Blood samples were collected to assess malondialdehyde (MDA), glutathione peroxidase (GPx), superoxide dismutase (SOD) and total antioxidant status (TAS) on day fifteen. Results: Single dose injection of cisplatin (1mg/kg) could cause a significant hyperalgesia on days 5, 10 and 15. CIH was abolished by daily administration of silymarin (50 and 100mg/kg) on days 10 and 15. Serum MDA level was decreased in cisplatin and silymarin (100 mg/kg) co-treated rats, while there was an increase in GPx, SOD as well as TAS parameters. Conclusion: The results of this study revealed that silymarin prevents from CIH possibly by improving lipid peroxidation and oxidative stress biomarkers. Other clinical studies should be performed to establish possible use of silymarin for treatment of CIH in susceptible individuals.

查看原文本刊更多论文

水飞蓟素通过抑制氧化应激减轻雄性大鼠顺铂诱导的痛症过敏

简介:顺铂是一种抗肿瘤药物，用于治疗多种癌症。然而，其临床应用与氧化应激介导的神经性疼痛有关。本研究旨在探讨水飞蓟素对雄性大鼠顺铂致痛症(CIH)和氧化应激生物标志物的影响。方法:将56只雄性大鼠随机分为7组。腹腔单次给药顺铂(1mg/kg)引起痛觉过敏，采用甩尾法评估。在第1、5、10和15天分别研究水飞蓟素(25、50和100 mg/kg/d，连用15 d)对CIH的影响。第15天采集血中丙二醛(MDA)、谷胱甘肽过氧化物酶(GPx)、超氧化物歧化酶(SOD)和总抗氧化状态(TAS)。结果:单次注射顺铂(1mg/kg)可在第5、10、15天引起明显的痛觉过敏。在第10天和第15天，每天给药水飞蓟素(50和100mg/kg)可消除CIH。顺铂与水飞蓟素(100 mg/kg)共处理大鼠血清MDA水平降低，GPx、SOD及TAS参数升高。结论:水飞蓟素可能通过改善脂质过氧化和氧化应激生物标志物来预防CIH的发生。应进行其他临床研究，以确定水飞蓟素在易感个体中治疗CIH的可能性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Physiology and Pharmacology PHYSIOLOGY-

CiteScore

0.70

自引率

0.00%

发文量

期刊介绍： Physiology and Pharmacology is the official English publication of the Iranian Society of Physiology and Pharmacology. The journal publishes Review articles, Full-length original articles, Letter to editor and Short communications in physiology, pharmacology and related subjects. The aim of this journal is to provide a medium of scientific communication for investigators in the field of Physiology and Pharmacology. The editors will welcome original basic and applied research articles from Physiologists and Pharmacologists. Articles should be in English language. The papers submitted to this journal must not be Published or under consideration for publication elsewhere. Physiology and Pharmacology is an open access journal which means that all contents is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search or link to the full text of the articles in this journal without asking prior permission from the publisher or the author.